41% af de patienter, der var i behandling med Raptiva, og hos 24% af de patienter, der fik placebo i en behandlingsperiode på 12 uger.
In large placebo-controlled clinical studies, these reactions were observed in approximately 41% of Raptiva-treated patients and 24% in placebo-treated patients over 12 weeks of treatment.